Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: Comparative study of immunohistochemistry and fluorescent in situ hybridization

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 57-63

  Matsubara, Hiroyuki ^a   Yamada, Yoshiaki ^a   Naruse, Katsuya ^a   Nakamura, Kogenta ^a   Aoki, Shigeyuki ^a   Taki, Tomohiro ^a   Tobiume, Motoi ^a   Zennami, Kenji ^a   Katsuda, Remi ^a   Honda, Nobuaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fluorescent in situ hybridization; HER 2 neu; Immunohistochemistry; Invasive bladder carcinoma; Molecular targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; MOLECULAR THERAPY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 38749099748     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.57     Document Type: Article

References (30)

1. Bassi P, Ferrante GD, Piazza N, et al: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 161: 1494-1497, 1999.
2. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA and Ashamallah A: Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 158: 393-399, 1997.
3. Schuster TG, Smith DC and Montie JE: Pelvic recurrences post cystectomy: current treatment strategies. Semin Urol Oncol 19: 45-50, 2001.
4. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
5. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
6. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066-1073, 1992.
7. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15: 2564-2569, 1997.
8. Bajorin DF, McCaffrey JA, Dodd PM, et al: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase trial evaluating two dosing schedules. Cancer 88: 1671-1678, 2000.
9. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
10. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608, 2005.
11. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The world health organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22: 1435-1448, 1998.
12. Sobin LH and Wittekind C (eds): TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, New York, pp 199-202, 2002.
13. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
14. Natali PG, Nicotra MR, Bigotti A, et al: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Intl Cancer 45: 457-461, 1990.
15. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
16. Gorgoulis VG, Barbatis C, Poulias I and Karameris AM: Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol 8: 758-764, 1995.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
18. Siamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
19. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
20. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
21. Mass RD, Press MF, Anderson S, et al: Evaluation of clinical outcomes according to HER-2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6: 240-246, 2005.
22. Dybdal N, Leiberman G, Anderson S, et al: Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 93: 3-11, 2005.
23. Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A and Syrjanen K: Use of immunohistochemically demonstrated c-erbB-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 20: 238-242, 1991.
24. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al: Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95: 1009-1015, 2002.
25. Miyamoto H, Kubota Y, Noguchi S, et al: C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55: 679-683, 2000.
26. Ioachim E, Charchanti A, Stavropoulos NE, Skopelitou A, Athanassiou ED and Agnantis NJ: Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma. Histol Histopathol 15: 721-727, 2000.
27. Koyuncuoglu M, Kargi A, Cingoz S and Kirkali Z: Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters. Cancer Lett 126: 143-148, 1998.
28. Sauter G, Moch H, Moore D, et al: Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53: 2199-2203, 1993.
29. Kruger S, Weitsch G, Buttner H, et al: Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21: 981-987, 2002.
30. de Pinieux G, Colin D, Vincent-Salomon A, et al: Confrontation of immunohistochemistry and fluorescence in situ hybridization for the assessment of HER-2/neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch 444: 415-419, 2004.